Cat. No. | Product Name | Target | Signaling Pathways |
---|---|---|---|
T37085 |
Luxeptinib
|
Others | Others |
Luxeptinib (CG-806) is a novel pan-FLT3/pan-BTK inhibitor that is administered orally. It exhibits potent and reversible inhibition of these enzymes, acting through a non-covalent mechanism. Luxeptinib effectively induces cell cycle arrest, apoptosis, or autophagy in acute myeloid leukemia cells [1][2][3][4]. |